Total Payments
$231,282
2024 Payments
$13,900
Companies
61
Transactions
1,610
Medicare Patients
42,697
Medicare Billing
$2.2M
Payment Breakdown by Category
Other$158,443 (68.5%)
Food & Beverage$34,385 (14.9%)
Consulting$24,050 (10.4%)
Travel$13,770 (6.0%)
Education$634.52 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $157,943 | 77 | 68.3% |
| Food and Beverage | $34,385 | 1,436 | 14.9% |
| Consulting Fee | $24,050 | 21 | 10.4% |
| Travel and Lodging | $13,770 | 46 | 6.0% |
| Education | $634.52 | 29 | 0.3% |
| Honoraria | $500.00 | 1 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $37,417 | 133 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $36,610 | 123 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $30,522 | 258 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $24,877 | 70 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,315 | 94 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $11,259 | 86 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $11,129 | 46 | $0 (2024) |
| Amgen Inc. | $10,383 | 169 | $0 (2024) |
| PFIZER INC. | $10,031 | 76 | $0 (2024) |
| Lilly USA, LLC | $9,096 | 22 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13,900 | 174 | Novartis Pharmaceuticals Corporation ($4,486) |
| 2023 | $17,431 | 204 | Bayer Healthcare Pharmaceuticals Inc. ($7,215) |
| 2022 | $19,407 | 213 | E.R. Squibb & Sons, L.L.C. ($8,599) |
| 2021 | $8,532 | 140 | AstraZeneca Pharmaceuticals LP ($4,142) |
| 2020 | $8,172 | 73 | AstraZeneca Pharmaceuticals LP ($6,862) |
| 2019 | $38,310 | 271 | Novartis Pharmaceuticals Corporation ($9,159) |
| 2018 | $61,075 | 272 | Boehringer Ingelheim Pharmaceuticals, Inc. ($15,252) |
| 2017 | $64,455 | 263 | Janssen Pharmaceuticals, Inc ($13,935) |
All Payment Transactions
1,610 individual payment records from CMS Open Payments — Page 1 of 65
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $304.66 | General |
| 12/24/2024 | Medtronic, Inc. | — | Travel and Lodging | In-kind items and services | $271.94 | General |
| 12/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $6.56 | General |
| Category: Cardio-renal | ||||||
| 12/19/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $126.11 | General |
| Category: Cardiovascular | ||||||
| 12/18/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: DIABETES | ||||||
| 12/18/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Cardio-renal | ||||||
| 12/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $24.31 | General |
| Category: Cardiovascular | ||||||
| 12/07/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $29.19 | General |
| Category: Cardio-renal | ||||||
| 11/20/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: DIABETES | ||||||
| 11/19/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $25.78 | General |
| Category: Cardio-renal | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $26.02 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/16/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $52.14 | General |
| Category: Cardiovascular | ||||||
| 11/16/2024 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $50.42 | General |
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $27.34 | General |
| Category: Cardiovascular | ||||||
| 11/13/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.21 | General |
| Category: Cardiovascular | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: Cardiology | ||||||
| 10/30/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: Genetic Disease | ||||||
| 10/24/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $24.69 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 10/24/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $17.74 | General |
| 10/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $21.60 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/21/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $14.55 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/15/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $26.19 | General |
| Category: Obesity | ||||||
| 10/14/2024 | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | LifeVest (Device) | Food and Beverage | Cash or cash equivalent | $23.43 | General |
| Category: Electromedical and Electrotherapeutic Apparatus | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 35 | 10,164 | 35,537 | $2.0M | $597,541 |
| 2022 | 34 | 10,519 | 27,591 | $1.9M | $511,833 |
| 2021 | 33 | 10,885 | 26,820 | $2.1M | $587,866 |
| 2020 | 36 | 11,129 | 26,113 | $2.1M | $523,528 |
Total Patients
42,697
Total Services
116,061
Medicare Billing
$2.2M
Procedure Codes
138
All Medicare Procedures & Services
138 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 568 | 909 | $375,607 | $116,068 | 30.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 728 | 1,424 | $491,280 | $115,779 | 23.6% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 26 | 12,212 | $158,756 | $109,203 | 68.8% |
| 83880 | Natriuretic peptide (heart and blood vessel protein) level | Office | 2023 | 467 | 991 | $108,797 | $37,878 | 34.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 809 | 1,788 | $123,372 | $29,416 | 23.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 836 | 1,921 | $105,655 | $25,029 | 23.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 833 | 2,092 | $73,220 | $21,601 | 29.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 821 | 2,119 | $127,140 | $20,713 | 16.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 847 | 2,196 | $35,136 | $18,148 | 51.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 826 | 2,033 | $65,056 | $15,441 | 23.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 49 | 327 | $23,544 | $13,627 | 57.9% |
| 82977 | Glutamyltransferase (liver enzyme) level | Office | 2023 | 825 | 1,861 | $53,969 | $13,045 | 24.2% |
| 82550 | Creatine kinase (cardiac enzyme) level, total | Office | 2023 | 836 | 1,916 | $51,732 | $12,128 | 23.4% |
| 83735 | Magnesium level | Office | 2023 | 709 | 1,508 | $42,224 | $9,843 | 23.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 93 | 99 | $36,333 | $9,691 | 26.7% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 49 | 330 | $22,440 | $6,058 | 27.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $14,869 | $4,466 | 30.0% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 34 | 383 | $13,022 | $2,706 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $10,327 | $2,648 | 25.6% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 215 | 265 | $10,600 | $2,507 | 23.7% |
| 85610 | Blood test, clotting time | Office | 2023 | 64 | 496 | $7,936 | $2,083 | 26.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 12 | $5,769 | $1,585 | 27.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 15 | 18 | $4,950 | $1,424 | 28.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 16 | 19 | $3,686 | $1,145 | 31.1% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 77 | 78 | $7,800 | $1,096 | 14.0% |
About Dr. Frank Mcgrew, MD
Dr. Frank Mcgrew, MD is a Cardiovascular Disease healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1922190396.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frank Mcgrew, MD has received a total of $231,282 in payments from pharmaceutical and medical device companies, with $13,900 received in 2024. These payments were reported across 1,610 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($157,943).
As a Medicare-enrolled provider, Mcgrew has provided services to 42,697 Medicare beneficiaries, totaling 116,061 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 138 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Memphis, TN
- Active Since 09/29/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1922190396
Products in Payments
- JARDIANCE (Drug) $39,451
- XARELTO (Drug) $36,610
- ENTRESTO (Drug) $23,889
- ELIQUIS (Drug) $18,009
- CAMZYOS (Drug) $15,212
- FARXIGA (Drug) $11,239
- Kerendia (Drug) $11,026
- PRALUENT (Drug) $10,907
- Repatha (Biological) $9,278
- PRADAXA (Drug) $6,524
- LEQVIO (Drug) $6,253
- BEVYXXA (Drug) $5,874
- NORTHERA (Drug) $5,585
- LifeVest (Device) $4,414
- PRALUENT ALIROCUMAB INJECTION (Biological) $3,128
- Sotalol Hydrochloride (Drug) $1,124
- MICRA (Device) $878.35
- Corlanor (Drug) $838.94
- Micra (Device) $700.53
- VERQUVO (Drug) $622.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Memphis
Dmitry Yaranov, Md, MD
Cardiovascular Disease — Payments: $600,772
Cardiovascular Disease $600,772
Steven Gubin, Md, MD
Cardiovascular Disease — Payments: $401,952
Cardiovascular Disease $401,952
Dwight Dishmon, Md, MD
Cardiovascular Disease — Payments: $210,097
Cardiovascular Disease $210,097
Claro Diaz, Md, MD
Cardiovascular Disease — Payments: $174,401
Cardiovascular Disease $174,401
Stevan Himmelstein, Md, MD
Cardiovascular Disease — Payments: $77,954
Cardiovascular Disease $77,954
Dr. Ikechukwu Ifedili, Md, MD
Cardiovascular Disease — Payments: $74,694
Cardiovascular Disease $74,694